AR133886A1 - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- AR133886A1 AR133886A1 ARP240102527A ARP240102527A AR133886A1 AR 133886 A1 AR133886 A1 AR 133886A1 AR P240102527 A ARP240102527 A AR P240102527A AR P240102527 A ARP240102527 A AR P240102527A AR 133886 A1 AR133886 A1 AR 133886A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- salts
- novel compounds
- tautomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de la fórmula (I), un tautómero de un compuesto de la fórmula (I) o una de sus sales. Un compuesto de la fórmula (VII), un tautómero de un compuesto de la fórmula (VII) o una de sus sales. Un compuesto de la fórmula (V), un tautómero de un compuesto de la fórmula (V) o una de sus sales. Una composición farmacéutica que comprende el compuesto o uno de sus tautómeros o sales farmacéuticamente aceptables según cualquiera de las reivindicaciones precedentes y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23382956 | 2023-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133886A1 true AR133886A1 (es) | 2025-11-12 |
Family
ID=88237493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240102527A AR133886A1 (es) | 2023-09-22 | 2024-09-20 | Compuestos novedosos |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20260001865A1 (es) |
| AR (1) | AR133886A1 (es) |
| TW (1) | TW202530192A (es) |
| WO (1) | WO2025061906A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| IL301626A (en) | 2020-09-30 | 2023-05-01 | Astrazeneca Ab | Compounds and their use in treating cancer |
| CA3199074A1 (en) * | 2020-10-21 | 2022-04-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor protein |
| CN117580575A (zh) * | 2021-06-17 | 2024-02-20 | 南京明德新药研发有限公司 | 戊二酰亚胺取代的异噁唑稠环化合物及其应用 |
| CN119301111A (zh) * | 2022-03-24 | 2025-01-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物 |
-
2024
- 2024-09-20 AR ARP240102527A patent/AR133886A1/es unknown
- 2024-09-20 TW TW113135774A patent/TW202530192A/zh unknown
- 2024-09-20 WO PCT/EP2024/076364 patent/WO2025061906A1/en active Pending
-
2025
- 2025-06-30 US US19/254,759 patent/US20260001865A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025061906A1 (en) | 2025-03-27 |
| TW202530192A (zh) | 2025-08-01 |
| US20260001865A1 (en) | 2026-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR133619A1 (es) | Compuestos de triazina | |
| CL2023003041A1 (es) | Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica | |
| MX2022011283A (es) | Compuestos pirimidoheterocíclicos y aplicación de los mismos. | |
| ECSP23002606A (es) | Nuevo inhibidor de la secreción de ácido y uso del mismo | |
| AR131493A1 (es) | Inhibidores de malt1 | |
| AR131639A1 (es) | Inhibidores de kif18a y usos de los mismos | |
| CO2024003094A2 (es) | Compuesto imidazocíclico y aplicación del mismo | |
| CL2022002817A1 (es) | Inhibidores de replicación del virus de inmunodeficiencia humana | |
| MX2022002941A (es) | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. | |
| AR128932A1 (es) | Inhibidores de bcl-xl | |
| CO2024011857A2 (es) | Compuestos de uracilo n3-sustituidos como inhibidores de trpa1 | |
| AR129185A1 (es) | Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina | |
| AR133886A1 (es) | Compuestos novedosos | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| AR130303A1 (es) | Compuestos de pirazolilsulfonamida y su uso terapéutico | |
| MX2023001865A (es) | Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este. | |
| AR132166A1 (es) | Inhibidores de inflamasoma nlrp3 y usos de los mismos | |
| AR129212A1 (es) | Compuestos piridona como inhibidores de trpa1 | |
| MX2024004551A (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana. | |
| AR131855A1 (es) | Inhibidores de quinasa dependientes de ciclina (cdk2) | |
| AR132661A1 (es) | Quinoxalinas substituidas | |
| AR133738A1 (es) | Inhibidores de cdk2 y sus usos | |
| AR128792A1 (es) | Composiciones de galnac para mejorar la biodisponibilidad de sirna | |
| AR129588A1 (es) | Inhibidores de kras | |
| AR132167A1 (es) | Inhibidores de fgfr2 y fgfr3 y usos de los mismos |